Sign in
CompletedPhase 2

A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Key facts

Who runs it
Enlivex Therapeutics Ltd.
Where
Belgium, France, Israel, Netherlands, and Spain31 sites in 5 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
148 people enrolled
Started
30 Nov 2020
Ended
16 Dec 2024
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Allocetra-OTS
  • Placebo
Record updated
19 August 2025

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Male or female ≥18 years and ≤90 years of age
  • Meets Sepsis 3 criteria with a SOFA score ≥5 above pre-admission status
  • Sepsis due to infection in at least one of the below organs:; 3.1. Community-Acquired Pneumonia (CAP). 3.2. Urinary tract infection 3.3. Acute cholecystitis diagnosed by Tokyo criteria 3.4. Acute cholangitis diagnosed by Tokyo criteria 3.5. Other intra-abdominal infections (IAI) 3.6. Skin or soft tissue infection
  • Adequate source control

Who cannot take part

  • Known immunocompromised state or medications known to be immunosuppressive
  • Organ allograft or previous history of stem cell transplantation
  • Sepsis due to infection other than lung infection, UTI, IAI, skin/soft tissue infection or sepsis patients where site of infection is unclear or unknown
  • Patients with nosocomial infection
  • A known malignancy
  • Patients with end-stage disease (unrelated to sepsis)
  • Known active symptomatic SARS-CoV-2 or chronic viral infections, such as HBV or HCV, HIV or other chronic infections
  • Chronic respiratory disease
  • Known NYHA class IV heart failure or unstable angina, ventricular arrhythmias, acute coronary disease or myocardial infarction
  • On chronic dialysis
  • Patients with acute pancreatitis
  • Moribund patients
  • Weight <50 kg or >120 kg or BMI >40 kg/m\^2
  • SOFA score ≥14 at screening
  • Known active upper GI tract ulceration or hepatic dysfunction

This trial has no sites in United States.

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

The 4 groups in the trial

  • Cohort 1Placebo, for comparison

    Single IV dose of placebo solution

    Treatment: Placebo

  • Cohort 2Treatment being tested

    Single IV dose of 5x10\^9 Allocetra-OTS cells in suspension

    Treatment: Allocetra-OTS

  • Cohort 3Treatment being tested

    Single IV dose of 10x10\^9 Allocetra-OTS cells in suspension

    Treatment: Allocetra-OTS

  • Cohort 4Treatment being tested

    Single or two doses of 10x10\^9 Allocetra-OTS cells in suspension

    Treatment: Allocetra-OTS

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
Record updated
19 August 2025